Femasys Inc. (FEMY) Bundle
A Brief History of Femasys Inc. (FEMY)
Company Overview
Company Overview
Femasys Inc. (NASDAQ: FEMY) is a medical technology company based in the United States, focused on developing and commercializing innovative products for women’s health care. The company was founded in 2004 and has since aimed to improve access to essential medical treatments for women.
Key Developments
- 2004: Femasys was established.
- 2018: Femasys received FDA clearance for its first product, the FemVue® Saline Infusion Sonohysterography (SIS) system.
- 2020: The company went public through an initial public offering (IPO), raising approximately $14 million.
- 2021: Femasys received 510(k) clearance from the FDA for its FemCath® product line.
- 2022: Launched FemVue® in additional market territories, expanding its reach beyond the U.S.
Financial Performance
Femasys reported the following key financial figures for the year ended December 31, 2022:
| Financial Metric | Amount (in millions) |
|---|---|
| Revenue | $4.5 |
| Net Loss | ($8.2) |
| Total Assets | $15.3 |
| Cash and Cash Equivalents | $6.1 |
| Total Liabilities | $5.9 |
Market Strategy
The company has focused its strategy on developing minimally invasive products that improve the diagnostic capabilities and treatment options in various areas of women’s health. Key points of their strategy include:
- Innovative Product Development: Continuous improvement and expansion of product lines.
- Strategic Partnerships: Collaborations with healthcare providers and organizations to enhance product reach.
- Market Expansion: Targeting new geographical markets while ensuring compliance with local regulations.
Recent Financial Performance (2023)
As of Q2 2023, Femasys reported the following financial metrics:
| Financial Metric | Amount (in millions) |
|---|---|
| Quarterly Revenue | $2.2 |
| Quarterly Net Loss | ($3.1) |
| Cash Burn Rate | ($1.5) |
| Projected Revenue Growth (2023) | 25% |
Stock Performance
As of October 2023, the stock price of Femasys Inc. (FEMY) is as follows:
| Date | Share Price (USD) | Market Capitalization (in millions) |
|---|---|---|
| October 1, 2023 | $1.10 | $20.0 |
| October 5, 2023 | $1.05 | $19.0 |
| October 10, 2023 | $1.15 | $21.5 |
Future Outlook
Looking ahead, analysts project that Femasys will focus on expanding its product line and entering additional markets, with anticipated revenue projections suggesting continued growth in the coming years.
A Who Owns Femasys Inc. (FEMY)
Major Shareholders
The ownership structure of Femasys Inc. (FEMY) is composed of a variety of institutional and individual investors. The latest data from the end of Q3 2023 indicates significant shareholders as follows:
| Shareholder Type | Name | Percentage Owned | Number of Shares |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 10.5% | 1,200,000 |
| Institutional Investor | The Vanguard Group, Inc. | 8.9% | 1,050,000 |
| Individual Investor | Femi Nazari | 5.2% | 600,000 |
| Institutional Investor | Wellington Management Co. LLP | 4.7% | 500,000 |
| Individual Investor | Elizabeth Green | 3.5% | 400,000 |
Insider Ownership
Insider ownership reflects the confidence of company executives in Femasys Inc. The breakdown as of October 2023 includes:
| Insider Name | Title | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Dr. Teresa G. Sweeney | CEO | 300,000 | 2.5% |
| Dr. James S. Caldwell | CTO | 150,000 | 1.2% |
| Linda J. Johnson | CFO | 100,000 | 0.8% |
Recent Stock Performance
The stock performance of Femasys Inc. has seen fluctuations throughout 2023. As of October 2023, key financial metrics include:
| Date | Stock Price | Market Capitalization | Trading Volume |
|---|---|---|---|
| October 1, 2023 | $7.10 | $85 million | 150,000 |
| October 15, 2023 | $6.80 | $80 million | 200,000 |
| October 31, 2023 | $7.25 | $88 million | 170,000 |
Financial Overview
Femasys has shown variable revenue streams. The most recent financial report for Q3 2023 provides the following statistics:
| Metric | Q3 2023 | Q3 2022 |
|---|---|---|
| Total Revenue | $3.2 million | $2.8 million |
| Net Loss | $1.5 million | $1.2 million |
| Cash Reserves | $10 million | $8 million |
Femasys Inc. (FEMY) Mission Statement
Core Objectives
The mission of Femasys Inc. is centered around improving reproductive health and providing innovative solutions in women's healthcare. The company aims to develop and commercialize products that address unmet needs in this field.
Vision and Values
Femasys Inc. emphasizes a commitment to excellence, innovation, and compassion. The following values guide their operations:
- Integrity - Adhering to ethical standards and practices.
- Innovation - Continuously seeking to improve and develop new technologies.
- Collaboration - Working with partners and communities to enhance healthcare.
- Quality - Focusing on producing high-quality products and services.
Financial Overview
As of the most recent financial reports, Femasys Inc. has demonstrated steady performance in the market. Key financial statistics include:
| Metric | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|
| Revenue ($) | 2.1 million | 1.9 million | 1.5 million |
| Net Income ($) | (1.5 million) | (1.7 million) | (1.6 million) |
| Total Assets ($) | 15 million | 14.5 million | 14 million |
| Total Liabilities ($) | 5 million | 4.8 million | 5 million |
| Cash Position ($) | 7 million | 6 million | 5.5 million |
Market Strategy
Femasys Inc. aims to penetrate the market through various strategic initiatives:
- Product Development - Investing in R&D to innovate products such as the FemVue and FemSelect systems.
- Market Expansion - Focusing on both domestic and international markets to increase accessibility.
- Partnerships - Collaborating with healthcare providers and organizations to enhance distribution channels.
Recent Achievements
In recent quarters, Femasys Inc. has achieved notable milestones:
- Received FDA clearance for new products aimed at fertility and reproductive health.
- Successfully conducted clinical trials demonstrating the efficacy of their systems.
- Expanded their customer base by establishing new contracts with leading healthcare institutions.
Future Goals
Femasys Inc. aims to continue its trajectory of growth and development with the following goals:
- Increase Revenue - Targeting $10 million in revenue by the end of 2024.
- Expand Product Line - Launching at least two new product lines in the next 18 months.
- Market Penetration - Achieving a 25% market share in the reproductive health device market by 2025.
How Femasys Inc. (FEMY) Works
Company Overview
Company Overview
Femasys Inc. (Ticker: FEMY) is a medical technology company that focuses on women's health, particularly in the areas of reproductive health and fertility. The company is known for its innovative products designed to address unmet needs in the fertility market. Femasys was founded in 2004 and is headquartered in Duluth, Georgia.
Product Portfolio
The core offerings of Femasys include:
- FemVue: A system for saline infusion sonography to evaluate the uterus.
- FemCath: A catheter system designed for intrauterine insemination.
- FemaSeed: A device aimed at facilitating natural conception.
Financial Performance
As of the third quarter of 2023, Femasys reported the following financial metrics:
| Metric | Value |
|---|---|
| Revenue | $2.3 million |
| Net Loss | -$1.5 million |
| Cash and Cash Equivalents | $18.4 million |
| R&D Expenses | $800,000 |
| Operating Expenses | $2.1 million |
Market Potential
The global fertility services market size was valued at approximately $22 billion in 2022 and is projected to reach $43 billion by 2030, growing at a CAGR of about 9% during the forecast period. Femasys aims to capture a significant share of this expanding market.
Recent Developments
In October 2023, Femasys announced the completion of a $10 million financing round aimed at accelerating product development and market expansion.
Partnerships and Collaborations
Femasys collaborates with various healthcare institutions and fertility specialists to further enhance its product offerings. Notable partnerships include:
- Partnership with Major Fertility Clinics: Engaged in clinical trials to validate the efficacy of their devices.
- Collaboration with Research Institutions: Focused on developing new technologies in reproductive health.
Stock Performance
As of October 15, 2023, the stock price of Femasys Inc. is $1.75, with a market capitalization of approximately $45 million. The stock has experienced a year-to-date decline of 15%.
Regulatory Approvals
Femasys has received several regulatory clearances from the FDA for its products:
- FemVue: FDA-cleared since 2019 for use in saline infusion sonography.
- FemCath: Approved in 2021 for intrauterine insemination procedures.
Competitive Landscape
Femasys faces competition from various players in the fertility space, including:
- CooperSurgical: Offers a broad range of fertility and gynecological products.
- Progyny: Provides employer-sponsored fertility and family-building benefits.
Future Outlook
Analysts predict revenue growth for Femasys due to increasing demand for fertility treatments and innovative technologies. Expected revenue for 2024 is projected at $4 million.
How Femasys Inc. (FEMY) Makes Money
Product Revenue
Femasys Inc. specializes in developing and commercializing innovative medical devices specifically focused on women's reproductive health. The company's revenue primarily stems from its product offerings, with a notable emphasis on its FemVue and FemCath systems.
| Product | Year Launched | 2022 Revenue (in $ millions) | 2021 Revenue (in $ millions) |
|---|---|---|---|
| FemVue | 2019 | 0.8 | 0.5 |
| FemCath | 2020 | 1.2 | 1.0 |
| Other Products | - | 0.5 | 0.4 |
Service Revenue
In addition to product sales, Femasys also generates revenue through service contracts and consulting services provided to healthcare institutions. This segment has seen gradual growth, contributing to the firm’s financial health.
| Service Type | 2022 Revenue (in $ millions) | 2021 Revenue (in $ millions) |
|---|---|---|
| Consulting Services | 0.3 | 0.2 |
| Service Contracts | 0.4 | 0.3 |
Market Expansion Strategies
Femasys is actively pursuing market expansion strategies, which include partnerships and collaborations with healthcare providers. These strategies are expected to enhance product reach and drive revenue growth.
- In 2021, Femasys entered into a partnership with several clinics to enhance distribution.
- Plans to launch new products in 2023 aimed at expanding their footprint in women’s health markets.
- Projected increase in revenue from new products expected to be around $2 million in 2023.
Research and Development Investments
The company invests heavily in research and development (R&D) to innovate and improve its product lines. In 2022, Femasys allocated approximately $2 million towards R&D efforts aimed at creating new technologies for reproductive health.
| Year | R&D Investment (in $ millions) | New Product Development |
|---|---|---|
| 2021 | 1.5 | 2 |
| 2022 | 2.0 | 3 |
| 2023 (Projected) | 2.5 | 4 |
Financial Performance Metrics
Femasys has shown a steady increase in revenue, reflecting its growing presence in the market. Below are recent financial performance metrics associated with the company's operations.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Total Revenue (in $ millions) | 3.0 | 2.0 | 1.5 |
| Net Income (in $ millions) | -1.5 | -1.2 | -1.0 |
| Gross Margin (%) | 65% | 60% | 55% |
Future Revenue Streams
Femasys is exploring additional revenue streams such as international sales and new product lines that may include telemedicine solutions and digital health technologies. The company forecasts potential revenue from these initiatives to be around $1 million in 2024.
- Increased focus on telehealth solutions post-pandemic.
- Plans for launching an international sales strategy targeted towards Europe and Asia.
- Anticipated financial contributions from these initiatives to enhance overall profitability.
Femasys Inc. (FEMY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support